Carregando...
Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months
BACKGROUND AND OBJECTIVE: Sorafenib is recommended for treating advanced hepatocellular carcinoma. However, it is frequently discontinued because of adverse events, which greatly affects its therapeutic effects. Furthermore, because patients treated with sorafenib for a long period can presumably to...
Na minha lista:
| Publicado no: | Case Rep Oncol |
|---|---|
| Principais autores: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6243964/ https://ncbi.nlm.nih.gov/pubmed/30483103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000493853 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|